Lexicon Pharmaceuticals (NASDAQ:LXRX) CEO Michael Exton Acquires 30,064 Shares of Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) CEO Michael Exton purchased 30,064 shares of the stock in a transaction on Friday, November 6th. The shares were bought at an average cost of $1.66 per share, for a total transaction of $49,906.24. Following the transaction, the chief executive officer directly owned 328,496 shares in the company, valued at approximately $545,303.36. The trade was a 10.07% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX opened at $1.82 on Tuesday. The company has a market cap of $809.83 million, a price-to-earnings ratio of -13.00 and a beta of 1.10. Lexicon Pharmaceuticals, Inc. has a 1-year low of $1.10 and a 1-year high of $2.68. The company’s fifty day simple moving average is $1.80 and its 200 day simple moving average is $1.89. The company has a current ratio of 13.37, a quick ratio of 13.29 and a debt-to-equity ratio of 0.29.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.03. The company had revenue of $11.25 million during the quarter, compared to the consensus estimate of $4.14 million. Lexicon Pharmaceuticals had a negative net margin of 147.38% and a negative return on equity of 37.53%. On average, research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.16 earnings per share for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Pictet Asset Management Holding SA bought a new position in Lexicon Pharmaceuticals in the 3rd quarter valued at about $41,000. Profund Advisors LLC raised its position in shares of Lexicon Pharmaceuticals by 600.8% in the 3rd quarter. Profund Advisors LLC now owns 340,479 shares of the biopharmaceutical company’s stock valued at $638,000 after buying an additional 291,893 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter worth approximately $66,000. WINTON GROUP Ltd lifted its holdings in shares of Lexicon Pharmaceuticals by 69.4% during the 2nd quarter. WINTON GROUP Ltd now owns 43,200 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 17,700 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 2nd quarter worth approximately $28,000. Institutional investors own 74.70% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wall Street Zen raised Lexicon Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Sunday. Zacks Research lowered Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, August 3rd. Cantor Fitzgerald started coverage on Lexicon Pharmaceuticals in a research note on Monday, September 28th. They issued an “overweight” rating and a $8.00 price target on the stock. Citigroup increased their price target on Lexicon Pharmaceuticals from $3.10 to $3.40 and gave the company a “buy” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Wednesday, October 21st. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Lexicon Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $5.80.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious and chronic diseases. The company uses its drug discovery platform to identify small-molecule treatments designed to target specific biological pathways, with an emphasis on metabolic, cardiovascular and neurological conditions.

Lexicon’s commercial products include INPEFA (sotagliflozin), an oral medicine approved in the United States to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in certain adults with heart failure or type 2 diabetes and chronic kidney disease.